A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Arbaclofen (Primary)
- Indications Muscle spasticity
- Focus Registrational; Therapeutic Use
- Acronyms OS440-3004
- Sponsors Osmotica Pharmaceutical
- 10 Jan 2019 Status changed from recruiting to completed.
- 16 Dec 2018 This trial has been completed in Bulgaria (end date: 2018-12-03)
- 05 Mar 2018 Planned End Date changed from 1 Jan 2019 to 1 Apr 2019.